{"id":"flixotide-plus-foradil","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Hoarseness"},{"rate":null,"effect":"Nervousness/anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate is a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improving airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma control.","oneSentence":"Flixotide plus Foradil is a combination inhaler that delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (formoterol) to relax airway smooth muscle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:49.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT06905483","phase":"PHASE4","title":"Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":"COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease","enrollment":22},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT07318350","phase":"PHASE3","title":"Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-10","conditions":"Moderate Asthma","enrollment":174},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT05689983","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Asthma in Children, Nonadherence, Medication","enrollment":40},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT06234345","phase":"PHASE3","title":"Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1252},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00379288","phase":"PHASE3","title":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Asthma","enrollment":404},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT02440009","phase":"PHASE2, PHASE3","title":"A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2014-05","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":191},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT04671355","phase":"PHASE4","title":"TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD","status":"WITHDRAWN","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-04","conditions":"COPD","enrollment":""},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1479},{"nctId":"NCT01738087","phase":"PHASE2","title":"Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-11","conditions":"Asthmatic","enrollment":30},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT04124510","phase":"PHASE3","title":"Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy","status":"TERMINATED","sponsor":"Mundipharma Korea Ltd","startDate":"2019-11-26","conditions":"Asthma","enrollment":20},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT00394368","phase":"PHASE3","title":"EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-11","conditions":"Bronchial Asthma","enrollment":180},{"nctId":"NCT02972476","phase":"PHASE4","title":"Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2016-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT04271839","phase":"PHASE4","title":"Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients","status":"WITHDRAWN","sponsor":"Mundipharma Pharmaceuticals S.L.","startDate":"2020-06-11","conditions":"Persistent Asthma","enrollment":""},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT01794780","phase":"PHASE4","title":"A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-05","conditions":"COPD","enrollment":2229},{"nctId":"NCT02477397","phase":"PHASE3","title":"Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2015-05-01","conditions":"COPD","enrollment":201},{"nctId":"NCT03387241","phase":"PHASE3","title":"Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years","status":"UNKNOWN","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2017-06-02","conditions":"Asthma","enrollment":330},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423},{"nctId":"NCT02811315","phase":"","title":"Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice.","status":"WITHDRAWN","sponsor":"Mundipharma Pharmaceuticals B.V.","startDate":"2016-07","conditions":"Asthma","enrollment":""},{"nctId":"NCT00563056","phase":"PHASE3","title":"An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2007-09","conditions":"Asthma Bronchiale","enrollment":227},{"nctId":"NCT00995800","phase":"PHASE2","title":"Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2009-10","conditions":"Asthma","enrollment":46},{"nctId":"NCT00475813","phase":"PHASE3","title":"Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2007-03","conditions":"Asthma","enrollment":211},{"nctId":"NCT02063139","phase":"PHASE2","title":"Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2014-02","conditions":"Mild Persistent Asthma","enrollment":48},{"nctId":"NCT00734318","phase":"PHASE3","title":"Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2008-09","conditions":"Asthma, Bronchial","enrollment":1667},{"nctId":"NCT01511367","phase":"PHASE3","title":"Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2012-03","conditions":"Asthma","enrollment":498},{"nctId":"NCT01946620","phase":"PHASE3","title":"A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2013-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1767},{"nctId":"NCT00476073","phase":"PHASE3","title":"Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2007-04","conditions":"Asthma Bronchiale","enrollment":228},{"nctId":"NCT01099722","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2010-04","conditions":"Asthma","enrollment":261},{"nctId":"NCT02753712","phase":"PHASE3","title":"A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2016-06-15","conditions":"Asthma","enrollment":105},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT02918487","phase":"NA","title":"Role of Herbs in the Management of Asthma","status":"UNKNOWN","sponsor":"Composite Interceptive Med Science","startDate":"2016-12","conditions":"Bronchial Asthma","enrollment":38},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02757209","phase":"NA","title":"Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD","status":"COMPLETED","sponsor":"Consorzio Futuro in Ricerca","startDate":"2016-04","conditions":"Asthma, COPD","enrollment":84},{"nctId":"NCT01332461","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":5677},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT00706446","phase":"NA","title":"The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06","conditions":"Asthma","enrollment":255},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01245569","phase":"PHASE3","title":"A Study in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":373},{"nctId":"NCT00901368","phase":"PHASE4","title":"FACTO Study (Foster® As Complete Treatment Option)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-05","conditions":"Asthmatic Patients","enrollment":431},{"nctId":"NCT00497237","phase":"PHASE3","title":"Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-04","conditions":"Asthma","enrollment":382},{"nctId":"NCT01570478","phase":"PHASE3","title":"A Study in Patients With Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-07","conditions":"Asthma","enrollment":108},{"nctId":"NCT02195375","phase":"PHASE2, PHASE3","title":"Flutiform® Compared With Seretide® in the Treatment of COPD","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2014-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":923},{"nctId":"NCT01845025","phase":"PHASE4","title":"Study of Safety of Foradil in Patients With Persistent Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05","conditions":"Persistent Asthma","enrollment":827},{"nctId":"NCT01321827","phase":"PHASE2, PHASE3","title":"Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2011-04","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":100},{"nctId":"NCT01393145","phase":"PHASE3","title":"Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD","status":"WITHDRAWN","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2011-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT02693769","phase":"PHASE2, PHASE3","title":"A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils","status":"TERMINATED","sponsor":"Mundipharma Research Limited","startDate":"2016-07","conditions":"ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)","enrollment":2},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT00479739","phase":"PHASE4","title":"CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Asthma","enrollment":700},{"nctId":"NCT01908140","phase":"PHASE3","title":"Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":933},{"nctId":"NCT01921127","phase":"","title":"Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-08","conditions":"COPD","enrollment":3000},{"nctId":"NCT02403713","phase":"PHASE1","title":"A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2014-08","conditions":"Asthma","enrollment":125},{"nctId":"NCT00961155","phase":"PHASE2","title":"Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With Asthma","status":"UNKNOWN","sponsor":"Medical University of Lodz","startDate":"2009-08","conditions":"Asthma","enrollment":200},{"nctId":"NCT00239421","phase":"PHASE4","title":"A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":605},{"nctId":"NCT01168310","phase":"PHASE2","title":"A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Dey","startDate":"2010-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":468},{"nctId":"NCT00774761","phase":"PHASE2","title":"A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2008-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":97},{"nctId":"NCT01836016","phase":"PHASE3","title":"A Randomized Comparative Effectiveness Research Trial of Three Treatments for COPD Patients","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2013-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":360},{"nctId":"NCT00542880","phase":"PHASE4","title":"Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":442},{"nctId":"NCT00314574","phase":"PHASE3","title":"A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Asthma","enrollment":850},{"nctId":"NCT00393991","phase":"PHASE3","title":"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-07","conditions":"Asthma","enrollment":475},{"nctId":"NCT00394199","phase":"PHASE3","title":"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-06","conditions":"Asthma","enrollment":357},{"nctId":"NCT00830102","phase":"PHASE2","title":"Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2004-10","conditions":"Asthma","enrollment":64},{"nctId":"NCT00393952","phase":"PHASE3","title":"New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-06","conditions":"Asthma","enrollment":557},{"nctId":"NCT00379028","phase":"PHASE4","title":"Airway Clearance Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT00242775","phase":"PHASE3","title":"Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":"Asthma","enrollment":2100},{"nctId":"NCT01255579","phase":"PHASE4","title":"Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2007-07","conditions":"Bronchial Asthma","enrollment":10},{"nctId":"NCT01186653","phase":"PHASE4","title":"Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2007-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":22},{"nctId":"NCT00394121","phase":"PHASE3","title":"New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-03","conditions":"Asthma","enrollment":400},{"nctId":"NCT00649025","phase":"PHASE3","title":"A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-03","conditions":"Asthma","enrollment":438},{"nctId":"NCT00734292","phase":"PHASE2","title":"Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-09","conditions":"Mild to Moderate Asthma","enrollment":39},{"nctId":"NCT00668408","phase":"PHASE4","title":"LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2008-05","conditions":"Lung Diseases, Obstructive, Chronic Heart Failure, Chronic Hypoxemia","enrollment":1000},{"nctId":"NCT00403286","phase":"PHASE2","title":"A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457},{"nctId":"NCT00646594","phase":"PHASE3","title":"Atlantis Symbicort","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Asthma","enrollment":1200},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600},{"nctId":"NCT00657774","phase":"PHASE1","title":"A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-04","conditions":"Asthma","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Flixotide plus Foradil","genericName":"Flixotide plus Foradil","companyName":"Mundipharma Research Limited","companyId":"mundipharma-research-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flixotide plus Foradil is a combination inhaler that delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (formoterol) to relax airway smooth muscle. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}